Vamikibart
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Vamikibart
- ebi 031
- Ebi-031
- EBI-031
- ebi031
- EBI031
- Immunoglobulin G2 [311-alanine], anti-(human interleukin 6) (human monoclonal RG6179 γ2-chain), disulfide with human monoclonal RG6179 κ-chain, dimer
- immunoglobulin g2 311 alanine anti human interleukin 6 human monoclonal rg6179 γ2 chain disulfide with human monoclonal rg6179 κ chain dimer
- immunoglobulin g2 kappa anti homo sapiens il6 interleukin 6 humanized and chimeric monoclonal antibody gamma2 heavy chain humanized 1 448 vh homo sapiens ighv1 69 11 86 7 ighd ighj5 02 90 9 l123 t 117 cdr imgt 8 8 15 26 33 51 58 97 111 1 122 homo sapiens ighg2 01 g2m ch2 v45 1 g2v8 ch2 a93 ch1 123 220 hinge 1 12 221 232 ch2 v45 1 283 h93 a 311 233 341 ch3 342 446 chs 447 448 123 448 136 218 disulfide with kappa light chain chimeric 1 218 v kappa musmus homsap mus musculus igkv3 2 01 79 8 igkj2 03 90 9 s120 q 104 homo sapiens igkv4 1 01 79 2 igkj2 01 100 cdr imgt 10 3 9 27 36 54 56 93 101 1 111 homo sapiens igkc 01 km3 a45 1 157 v101 195 112 218 dimer 224 224 225 225 228 228 231 231 tetrakisdisulfide produced in chinese hamster ovary cho cells cell line cho k1m glycoform alfa
- immunoglobulin G2-kappa, anti-[Homo sapiens IL6 (interleukin 6)], humanized and chimeric monoclonal antibody; gamma2 heavy chain humanized (1-448) [VH ( Homo sapiens IGHV1-69*11 (86.7%) -(IGHD) -IGHJ5*02 (90.9%) L123>T (117), CDR-IMGT [8.8.15] (26-33.51-58.97-111)) (1-122) - Homo sapiens IGHG2*01, G2m.. CH2 V45.1, G2v8 CH2 A93 (CH1 (123-220), hinge 1-12 (221-232), CH2 V45.1 (283), H93>A (311) (233-341), CH3 (342-446), CHS (447-448)) (123-448)], (136-218')-disulfide with kappa light chain chimeric (1'-218') [V-KAPPA Musmus/Homsap (Mus musculus IGKV3- 2*01 (79.8%) -IGKJ2*03 (90.9%) S120>Q (104)/Homo sapiens IGKV4-1*01 (79.2%) -IGKJ2*01 (100%), CDR-IMGT [10.3.9] (27-36.54-56.93-101)) (1'-111') -Homo sapiens IGKC*01, Km3 A45.1 (157), V101 (195) (112'-218')]; dimer (224-224'':225-225'':228-228'':231-231'')-tetrakisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1M, glycoform alfa
- recombinant humanised igg2 kappa anti interleukin 6 monoclonal antibody ro7200220
- RECOMBINANT HUMANISED IGG2 KAPPA ANTI-INTERLEUKIN 6 MONOCLONAL ANTIBODY RO7200220
- rg 6179
- RG-6179
- rg6179
- RG6179
- ro 7200220
- RO-7200220
- ro7200220
- RO7200220
- vamikibart
- Vamikibart
- vamikibart [INN]
- VAMIKIBART [USAN]
- Vamikibart [WHO-DD]
- vamikibart inn
And 2 more, listed on the interactive page.
- CAS registry numbers
- 2744320-12-3
- ChEMBL ID
- CHEMBL5315020
- FDA ingredient codes (UNII)
- KP04MH1JTT
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Drug name stem
- -bart
- Condition
- Macular Edema
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0003005
- Subject identifier
- D008269
- Condition
- Inflammation
- Highest recorded phase
- 2
- Condition identifier
- MP:0001845
- Subject identifier
- D007249
- Condition identifier
- EFO_0009321
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0003005
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004728
- Highest recorded phase
- 2
- Condition identifier
- MP_0001845
- NCT05642312
- NCT05642325
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Heavy chain
- Type
- Protein
- Sequence
- QVQLVQSGAEVKKPGSSVKVSCKASGYVLPNYLIEWVRQAPGQGLEWMGVTTPGGGTINYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSRWDPLYYYALEYWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVAQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
- Component
- Disulfide bridges
- Sequence
- 22-96 $ 22''-96'' $ 23'-92' $ 23'''-92''' $ 136-218' $ 136''-218''' $ 138'-198' $ 138'''-198''' $ 149-205 $ 149''-205'' $ 224-224'' $ 225-225'' $ 228-228'' $ 231-231'' $ 262-322 $ 262''-322'' $ 368-426 $ 368''-426''
- Component
- Light chain
- Type
- Protein
- Sequence
- DIVMTQSPDSLAVSLGERATINCRASESVDNYGIPFMNWYQQKPGQPPKLLIYAASNRGSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSEEVPLTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Glycosylation sites (N)
- Sequence
- 298 $ 298''
Related records
Trials (9)
- A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors
- A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema
- A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema
- A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema
- A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema
- Anti-IL6 and Corticosteroid Monotherapy vs Combination in COVID-19
- Interleukin 6-guided Antibiotic Prescriptions in AECOPD Inpatients
- Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema
- Vamikibart in Participants With Uveitic Macular Edema
In development for (2)
- Diabetic macular edema Phase 2
- Macular retinal edema Phase 3